AI Article Synopsis
- - The study aimed to determine if hepatic resection (HR) for breast cancer liver metastases (BCLM) leads to better survival outcomes than non-hepatic resection (NHR).
- - Researchers analyzed data from 384 BCLM patients between 2008 and 2018 using propensity score matching (PSM) to compare clinical outcomes.
- - Results showed HR significantly improved overall survival rates compared to NHR, particularly in patients with positive hormonal receptors, indicating HR may be a beneficial surgical option.
Article Abstract
Background: The role of surgery in breast cancer liver metastases (BCLM) remains elusive, and current application is limited. Our aim is to investigate whether hepatic resection (HR) of BCLM improves survival compared with non-hepatic resection (NHR) treatment.
Methods: Three hundred and eighty-four patients with BCLM from 2008 to 2018 were divided into two groups. Propensity score matching (PSM) analysis was used to compare the clinical outcomes.
Results: After PSM the mean overall survival (OS) and the 1, 3, and 5-year OS rates in HR group were 61.8 months, 92.6%, 54.7% and 54.7%, respectively; while for NHR group these values were 38.6 months, 79.2%, 45.6% and 21.9%, respectively (p < 0.007). Multivariate analysis indicated hormonal receptor status (p = 0.039) and hepatic resection (p = 0.032) were independent prognostic factors.
Conclusion: Our study revealed that hepatectomy yields a survival benefit safely compared with medical treatments, especially for patients with positive hormonal receptors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjsurg.2020.02.047 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!